- Home
- IMRN vs APLM Comparison
IMRN vs APLM Comparison
Compare IMRN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- APLM
- Stock Information
- Founded
- IMRN 1994
- APLM 2016
- Country
- IMRN Australia
- APLM United States
- Employees
- IMRN N/A
- APLM N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- IMRN Health Care
- APLM Finance
- Exchange
- IMRN Nasdaq
- APLM Nasdaq
- Market Cap
- IMRN 15.0M
- APLM 15.6M
- IPO Year
- IMRN N/A
- APLM N/A
- Fundamental
- Price
- IMRN $1.96
- APLM $9.75
- Analyst Decision
- IMRN Strong Buy
- APLM Strong Buy
- Analyst Count
- IMRN 1
- APLM 2
- Target Price
- IMRN $5.00
- APLM $425.00
- AVG Volume (30 Days)
- IMRN 6.0K
- APLM 102.2K
- Earning Date
- IMRN 12-31-2024
- APLM 02-15-2025
- Dividend Yield
- IMRN N/A
- APLM N/A
- EPS Growth
- IMRN N/A
- APLM N/A
- EPS
- IMRN N/A
- APLM N/A
- Revenue
- IMRN $3,271,194.00
- APLM $2,101,000.00
- Revenue This Year
- IMRN N/A
- APLM N/A
- Revenue Next Year
- IMRN N/A
- APLM N/A
- P/E Ratio
- IMRN N/A
- APLM N/A
- Revenue Growth
- IMRN 171.67
- APLM 70.54
- 52 Week Low
- IMRN $1.59
- APLM $6.50
- 52 Week High
- IMRN $5.96
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- IMRN 45.89
- APLM 50.39
- Support Level
- IMRN $2.05
- APLM $7.23
- Resistance Level
- IMRN $2.23
- APLM $8.88
- Average True Range (ATR)
- IMRN 0.17
- APLM 1.37
- MACD
- IMRN -0.00
- APLM 0.21
- Stochastic Oscillator
- IMRN 29.69
- APLM 57.91
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.